{
    "ticker": "FGEN",
    "name": "FibroGen, Inc.",
    "description": "FibroGen, Inc. is a biotechnology company focused on discovering, developing, and commercializing innovative therapeutics to treat serious diseases. Founded in 1993 and headquartered in San Francisco, California, FibroGen's mission is to improve the lives of patients by addressing unmet medical needs. The company's lead product candidate, roxadustat, is an oral therapy designed to treat anemia associated with chronic kidney disease (CKD). Roxadustat works by mimicking the body's natural response to low oxygen levels, stimulating the production of erythropoietin and hemoglobin. FibroGen is also advancing its pipeline of therapies targeting fibrotic diseases and cancer-related conditions. The company emphasizes research and development, leveraging its proprietary technology platforms to create novel treatments that have the potential to transform patient care. With a commitment to innovation and patient-centric solutions, FibroGen strives to deliver breakthrough therapies that can significantly improve health outcomes.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Francisco, California, USA",
    "founded": "1993",
    "website": "https://www.fibrogen.com",
    "ceo": "Patricia S. Hurter",
    "social_media": {
        "twitter": "https://twitter.com/FibroGen",
        "linkedin": "https://www.linkedin.com/company/fibrogen/"
    },
    "investor_relations": "https://investors.fibrogen.com",
    "key_executives": [
        {
            "name": "Patricia S. Hurter",
            "position": "CEO"
        },
        {
            "name": "Kathy H. M. B. Haller",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "Roxadustat"
            ]
        }
    ],
    "seo": {
        "meta_title": "FibroGen, Inc. | Innovative Therapeutics for Serious Diseases",
        "meta_description": "Learn about FibroGen, Inc., a biotechnology company dedicated to developing innovative therapies for anemia and fibrotic diseases. Discover our mission and product pipeline.",
        "keywords": [
            "FibroGen",
            "Biotechnology",
            "Roxadustat",
            "Anemia",
            "Chronic Kidney Disease",
            "Therapeutics"
        ]
    },
    "faq": [
        {
            "question": "What is FibroGen known for?",
            "answer": "FibroGen is known for developing innovative therapies to treat anemia and fibrotic diseases, particularly its lead product, roxadustat."
        },
        {
            "question": "Who is the CEO of FibroGen?",
            "answer": "Patricia S. Hurter is the CEO of FibroGen, Inc."
        },
        {
            "question": "Where is FibroGen headquartered?",
            "answer": "FibroGen is headquartered in San Francisco, California, USA."
        },
        {
            "question": "What is roxadustat?",
            "answer": "Roxadustat is an oral treatment for anemia associated with chronic kidney disease, designed to stimulate erythropoietin production."
        },
        {
            "question": "When was FibroGen founded?",
            "answer": "FibroGen was founded in 1993."
        }
    ],
    "competitors": [
        "AMGN",
        "REGN",
        "BMY",
        "GILD"
    ],
    "related_stocks": [
        "VRTX",
        "ALNY",
        "NVS",
        "MRNA"
    ]
}